<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue article.dtd?><?DTDIdentifier.IdentifierType system?><?SourceDTD.DTDName article.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName bmc2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med Genet</journal-id><journal-title-group><journal-title>BMC Medical Genetics</journal-title></journal-title-group><issn pub-type="epub">1471-2350</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2350-11-6</article-id><article-id pub-id-type="pmid">20078877</article-id><article-id pub-id-type="doi">10.1186/1471-2350-11-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research article</subject></subj-group></article-categories><title-group><article-title>Gene polymorphisms in association with emerging cardiovascular risk markers in adult women</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Fan</surname><given-names>Amy Z</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>afan@cdc.gov</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Yesupriya</surname><given-names>Ajay</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>aYesupriya@cdc.gov</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Chang</surname><given-names>Man-huei</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>mchang@cdc.gov</email></contrib><contrib contrib-type="author" id="A4"><name><surname>House</surname><given-names>Meaghan</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>meaghanhouse@gmail.com</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Fang</surname><given-names>Jing</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>JFang@cdc.gov</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Ned</surname><given-names>Ren&#x000e9;e</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>RNed@cdc.gov</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Hayes</surname><given-names>Donald</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>don.hayes@doh.hawaii.gov</email></contrib><contrib contrib-type="author" id="A8"><name><surname>Dowling</surname><given-names>Nicole F</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>ndowling@cdc.gov</email></contrib><contrib contrib-type="author" id="A9"><name><surname>Mokdad</surname><given-names>Ali H</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>mokdaa@u.washington.edu</email></contrib></contrib-group><aff id="I1"><label>1</label>National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA</aff><aff id="I2"><label>2</label>School of Public Health, Emory University, 1518 Clifton Road NE, Atlanta, GA 30329, USA</aff><aff id="I3"><label>3</label>Institute for Health Metrics and Evaluation, University of Washington, 2301 5th Avenue Suite600, Seattle, WA 98121, USA</aff><pub-date pub-type="collection"><year>2010</year></pub-date><pub-date pub-type="epub"><day>15</day><month>1</month><year>2010</year></pub-date><volume>11</volume><fpage>6</fpage><lpage>6</lpage><history><date date-type="received"><day>5</day><month>6</month><year>2009</year></date><date date-type="accepted"><day>15</day><month>1</month><year>2010</year></date></history><permissions><copyright-statement>Copyright &#x000a9;2010 Fan et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2010</copyright-year><copyright-holder>Fan et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.biomedcentral.com/1471-2350/11/6"/><abstract><sec><title>Background</title><p>Evidence on the associations of emerging cardiovascular disease risk factors/markers with genes may help identify intermediate pathways of disease susceptibility in the general population. This population-based study is aimed to determine the presence of associations between a wide array of genetic variants and emerging cardiovascular risk markers among adult US women.</p></sec><sec><title>Methods</title><p>The current analysis was performed among the National Health and Nutrition Examination Survey (NHANES) III phase 2 samples of adult women aged 17 years and older (sample size n = 3409). Fourteen candidate genes within <italic>ADRB2, ADRB3, CAT, CRP, F2, F5, FGB, ITGB3, MTHFR, NOS3, PON1, PPARG, TLR4</italic>, and <italic>TNF </italic>were examined for associations with emerging cardiovascular risk markers such as serum C-reactive protein, homocysteine, uric acid, and plasma fibrinogen. Linear regression models were performed using SAS-callable SUDAAN 9.0. The covariates included age, race/ethnicity, education, menopausal status, female hormone use, aspirin use, and lifestyle factors.</p></sec><sec><title>Results</title><p>In covariate-adjusted models, serum C-reactive protein concentrations were significantly (P value controlling for false-discovery rate &#x02264; 0.05) associated with polymorphisms in <italic>CRP </italic>(rs3093058, rs1205)<italic>, MTHFR </italic>(rs1801131)<italic>, and ADRB3 </italic>(rs4994). Serum homocysteine levels were significantly associated with <italic>MTHFR </italic>(rs1801133).</p></sec><sec><title>Conclusion</title><p>The significant associations between certain gene variants with concentration variations in serum C-reactive protein and homocysteine among adult women need to be confirmed in further genetic association studies.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Coronary heart disease and stroke remain the leading causes of death and disability for men and women in the United States [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. Atherosclerotic cardiovascular disease, which affects the heart, brain, and peripheral circulation, is responsible for the majority of the cases [<xref ref-type="bibr" rid="B3">3</xref>]. Traditional risk factors cannot fully account for the variation in the prevalence of heart disease in the general population. Some biomarkers, including C-reactive protein, fibrinogen, uric acid, and homocysteine, are among those which have been proposed as potential modifiable risk factors/markers in the last two decades.</p><p>Inflammation plays a key role in the initiation, progression, and outcome of atherosclerosis [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. In prospective studies, markers of inflammation such as C-reactive protein (CRP) and fibrinogen have been found to be predictive of atherosclerosis and an increased risk of CVD events [<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B16">16</xref>]. Elevated levels of plasma homocysteine and serum uric acid have been associated with increased risk of cardio- or cerebrovascular disease [<xref ref-type="bibr" rid="B17">17</xref>-<xref ref-type="bibr" rid="B21">21</xref>]. In addition, these emerging cardiovascular risk biomarkers influence each other and are correlated with conventional risk factors/markers such as high blood pressure or hyperlipidemia [<xref ref-type="bibr" rid="B22">22</xref>-<xref ref-type="bibr" rid="B24">24</xref>].</p><p>The concentrations of all four emerging biomarkers (CRP, fibrinogen, uric acid, homocysteine) are caused by complex interactions between environmental risk factors and predisposing genes. The candidate genes in this study, i.e., <italic>ADRB2, ADRB3, CAT, CRP, F2, F5, FGB, ITGB3, MTHFR, NOS3, PON1, PPARG, TLR4</italic>, and <italic>TNF</italic>, have been suggested to confer excess risk of cardiovascular disease, although the results are inconsistent from different association studies [<xref ref-type="bibr" rid="B25">25</xref>]. These candidate genes were selected from a set of variants that were previously genotyped in the NHANES III genetic data [<xref ref-type="bibr" rid="B26">26</xref>] and were identified from systematic literature reviews of previously published candidate gene association studies and meta-analyses [<xref ref-type="bibr" rid="B27">27</xref>-<xref ref-type="bibr" rid="B33">33</xref>].</p><p>The evidence on the associations of four novel risk factors/markers with these genes may help identify intermediate pathways of CVD susceptibility in the general population. For example, because genetic traits confer a risk of inflammation, common gene polymorphisms (&#x0003e; 1% frequency in the general population) may explain an individual's likelihood of developing inflammation or why some have a greater inflammatory response than others [<xref ref-type="bibr" rid="B34">34</xref>-<xref ref-type="bibr" rid="B36">36</xref>]. The National Health and Nutrition Examination Survey (NHANES) III DNA bank offers a unique sample to carry out this analysis as it has a large sample size and a diversity of ages, races and ethnicities that is representative of the US population. We examined the presence and magnitude of associations between candidate genetic variants (n = 27) within <italic>ADBR2, ADBR3, CAT, CRP, F2, F5, FGB, ITGB3, MTHFR, NOS3, PON1, PPARG, TLR4</italic>, and <italic>TNF </italic>[<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B37">37</xref>] and four cardiovascular risk markers (CRP, fibrinogen, homocysteine, and uric acid) among adult women.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Study Sample</title><p>Participants took part in the second phase (1991-1994) of the Third National Health and Nutrition Examination Survey (NHANES III). The NHANES are complex, multistage cross-sectional sample surveys conducted by the National Center for Health Statistics (NCHS) of the Centers for Disease Control and Prevention (CDC). NHANES III included a stratified multistage probability design to provide national estimates of common diseases and their respective risk factors for the civilian non-institutionalized population in the United States ages two months or older, from 1988 through 1994. Data collection for NHANES occurs at three levels: a brief household screener interview, an in-depth household survey interview, and an extensive medical examination [<xref ref-type="bibr" rid="B38">38</xref>]. Population weights are calculated for each individual to make the data representative of the US population. In the second phase of NHANES III, white blood cells were frozen and cell lines were immortalized with the Epstein- Barr virus, creating a DNA bank. The current analysis was performed among adult women aged 17 years and older (n = 3409). The study was approved by the NCHS Ethics Review Board. NHANES III DNA bank, selection of candidate genes and variants, genotyping methods, and quality controls are detailed elsewhere [<xref ref-type="bibr" rid="B26">26</xref>].</p></sec><sec><title>Genotyping Methods</title><p>Most genotypes were assayed either by TaqMan (5' nuclease assay; Applied Biosystems, Foster City, CA) or by the MGB Eclipse Assay (3' hybridization triggered fluorescence reaction; Nanogen, Bothwell, WA). <italic>ADRB2 </italic>and <italic>F2 </italic>were genotyped using pyrosequencing. Water controls and DNA samples with known genotypes, purchased from Coriell Cell Repository (Camden, NJ) were included on each well plate [<xref ref-type="bibr" rid="B26">26</xref>].</p></sec><sec><title>Biochemical Analysis</title><p>The laboratory procedures for the assessment of serum C reactive protein, serum uric acid, serum homocysteine and plasma fibrinogen are available from the NCHS website [<xref ref-type="bibr" rid="B39">39</xref>].</p></sec><sec><title>Covariates</title><p>Potential confounders of the gene-outcome relationship were selected a priori. Demographic characteristics include age (17-40 yrs, 41-59 yrs, 60 + yrs), race-ethnicity (non-Hispanic white, non-Hispanic black, Mexican American), and educational attainment (&#x0003c; 12 yrs, 12 yrs, college and above). Lifestyle factors include smoking status (current, former, never), drinking status (lifetime abstainer, former drinker, current drinker), total dietary fiber intake (&#x02265; or &#x0003c; 7 gm/1000 kcal), total energy intake (&#x02265; or &#x0003c; 1600 kcal per day), and physical activity (none, low, high). Other covariates include BMI (&#x0003c; 25 kg/m<sup>2</sup>, 25-29.9 kg/m<sup>2</sup>, &#x02265; 30 kg/m<sup>2</sup>), menopausal status (yes/no), female hormone use (yes/no), and aspirin use (yes/no). Details on descriptions of covariates are available elsewhere [<xref ref-type="bibr" rid="B32">32</xref>].</p></sec><sec><title>Statistical Analysis</title><p>Weighted allele frequencies of genetic variants in the US population by race/ethnicity using the NHANES III phase 2 DNA bank have been presented elsewhere [<xref ref-type="bibr" rid="B26">26</xref>].</p><p>Deviations from Hardy-Weinberg proportions were tested in a standard unweighted analysis using Chi-square goodness-of-fit approach. Point estimates and 95% confidence intervals for the distribution of the demographic, lifestyle and biomarker variables were calculated. The Taylor series linearization approach was used to estimate the variance for standard errors.</p><p>Adjusted means of the outcome variables (inflammation markers) by gene variants were obtained from multiple linear regression models. Candidate covariates/potential confounders included age, race/ethnicity, education, menopausal status, female hormone use, smoking status, drinking status, dietary fiber intake, total energy intake, physical activity, body mass index, and aspirin use. However, only significant covariates "in the crude models" were retained in fully-adjusted models for a specific marker predicted by certain genetic variants. For CRP, total energy intake was excluded; for fibrinogen, dietary fiber intake was excluded; for homocysteine, drinking status was excluded; and for uric acid, drinking status and aspirin use were excluded. Minimally adjusted models were also presented with adjustment of only race/ethnicity. We presented adjusted means by genotype [<xref ref-type="bibr" rid="B40">40</xref>] and made groupwise comparisons. A P value &#x02264; 0.05 of the Satterthwaite-adjusted F-statistic in fully adjusted models was considered as statistically significant. False Discovery Rate (FDR)-adjusted P values (adjusted for a maximum of 27 tests) are presented along with unadjusted P values from Wald Chi-square tests. All outcome variables were right-skewed and were thus log-transformed before analysis. The analyses were performed in SAS-callable SUDAAN 9.01 (Research Triangle Institute, NC, 2007) to account for the complex sampling design, non-response, and sample weights for Genetic Component of NHANES III.</p></sec></sec><sec><title>Results</title><p>Characteristics of the study population based on the 3,409 participants are described in Table <xref ref-type="table" rid="T1">1</xref>. The weighted frequency distribution was 81.3% non-Hispanic white, 13.2% non-Hispanic black, and 5.6% Mexican American. Current smokers accounted for 25.7% of the study population, while 43.3% were current drinkers. Approximately 41% of women have undergone menopause; and about 16% were currently using any form of female hormone. The correlation matrix for the four logarithm-transformed biomarkers is shown in Additional File <xref ref-type="supplementary-material" rid="S1">1</xref>: Table S1. The Pearson correlation coefficients ranged from 0.04 to 0.39.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Characteristics of study population of US women, Third National Health and Nutrition Examination Survey, Phase 2 (1991-1994)</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="left">Percent (Standard Error)</th></tr></thead><tbody><tr><td/><td align="left">N = 3,409</td></tr><tr><td align="left">Age</td><td/></tr><tr><td align="left">17-40</td><td align="left">45.6 (1.8)</td></tr><tr><td align="left">41-59</td><td align="left">30.2 (1.6)</td></tr><tr><td align="left">60+</td><td align="left">24.2 (2.2)</td></tr><tr><td align="left">Race/Ethnicity</td><td/></tr><tr><td align="left">&#x02003;Non-Hispanic white</td><td align="left">81.3 (1.8)</td></tr><tr><td align="left">&#x02003;Non-Hispanic black</td><td align="left">13.2 (1.7)</td></tr><tr><td align="left">&#x02003;Mexican American</td><td align="left">5.6 (0.8)</td></tr><tr><td align="left">Educational attainment</td><td/></tr><tr><td align="left">&#x02003;&#x0003c; 12 yrs</td><td align="left">22.1 (1.6)</td></tr><tr><td align="left">&#x02003;12 yrs</td><td align="left">37.5 (1.4)</td></tr><tr><td align="left">&#x02003;College or above</td><td align="left">40.4 (2.4)</td></tr><tr><td align="left">BMI (kg/m<sup>2</sup>)</td><td/></tr><tr><td align="left">&#x02003;&#x0003c; 25</td><td align="left">48.1 (1.9)</td></tr><tr><td align="left">&#x02003;25-29.9</td><td align="left">25.4 (0.8)</td></tr><tr><td align="left">&#x02003;&#x02265; 30</td><td align="left">26.5 (1.4)</td></tr><tr><td align="left">Smoking status</td><td/></tr><tr><td align="left">&#x02003;Current smoker</td><td align="left">25.7 (1.5)</td></tr><tr><td align="left">&#x02003;Former smoker</td><td align="left">18.7 (1.4)</td></tr><tr><td align="left">&#x02003;Never smoker</td><td align="left">55.6 (1.8)</td></tr><tr><td align="left">Drinking status</td><td/></tr><tr><td align="left">&#x02003;Lifetime abstainer</td><td align="left">17.9 (1.7)</td></tr><tr><td align="left">&#x02003;Former drinker</td><td align="left">38.8 (1.3)</td></tr><tr><td align="left">&#x02003;Current drinker</td><td align="left">43.3 (2.2)</td></tr><tr><td align="left">Total dietary fiber intake</td><td/></tr><tr><td align="left">&#x02003;&#x02265; 7 gm/1000 kcal</td><td align="left">59.8 (1.9)</td></tr><tr><td align="left">&#x02003;&#x0003c; 7 gm/1000 kcal</td><td align="left">40.2 (1.9)</td></tr><tr><td align="left">Total energy intake</td><td/></tr><tr><td align="left">&#x02003;&#x02265; 1600 kcal</td><td align="left">56.4 (1.4)</td></tr><tr><td align="left">&#x02003;&#x0003c; 1600 kcal</td><td align="left">43.6 (1.4)</td></tr><tr><td align="left">Physical activity</td><td/></tr><tr><td align="left">&#x02003;None</td><td align="left">22.7 (2.1)</td></tr><tr><td align="left">&#x02003;Low</td><td align="left">35.3 (1.1)</td></tr><tr><td align="left">&#x02003;High</td><td align="left">42.0 (1.9)</td></tr><tr><td align="left">Menopausal status</td><td/></tr><tr><td align="left">&#x02003;Yes</td><td align="left">40.7 (2.2)</td></tr><tr><td align="left">&#x02003;No</td><td align="left">59.3 (2.2)</td></tr><tr><td align="left">Aspirin use</td><td/></tr><tr><td align="left">&#x02003;None</td><td align="left">68.0 (1.2)</td></tr><tr><td align="left">&#x02003;&#x0003c; 1 day/month</td><td align="left">30.1 (1.1)</td></tr><tr><td align="left">&#x02003;&#x02265; 1 day/month</td><td align="left">1.8 (0.4)</td></tr><tr><td align="left">Female hormone use</td><td/></tr><tr><td align="left">&#x02003;Yes</td><td align="left">16.0 (1.4)</td></tr><tr><td align="left">&#x02003;No</td><td align="left">84.0 (1.4)</td></tr><tr><td align="left">Serum C-reactive protein (mg/dL)<sup>a</sup></td><td align="left">0.33 (0.31,0.35)</td></tr><tr><td align="left">Plasma fibrinogen (g/L)<sup>a</sup></td><td align="left">3.00 (2.95, 3.06)</td></tr><tr><td align="left">Serum homocysteine (umol/L)<sup>a</sup></td><td align="left">8.17 (8.01, 8.33)</td></tr><tr><td align="left">Serum uric acid (umol/L)<sup>a</sup></td><td align="left">270 (265, 276)</td></tr></tbody></table><table-wrap-foot><p><sup>a </sup>Data are geometric mean (95% confidence interval).</p></table-wrap-foot></table-wrap><p>In fully-adjusted models, serum C-reactive protein concentrations were significantly associated with polymorphisms in <italic>CRP </italic>(rs3093058, rs1205)<italic>, MTHFR </italic>(rs1801131)<italic>, ADRB3 </italic>(rs4994) (Table <xref ref-type="table" rid="T2">2</xref>). Plasma fibrinogen levels were significantly associated with <italic>TNF </italic>(rs1800750), though not after adjustment for multiple testing (Table <xref ref-type="table" rid="T3">3</xref>). Serum uric acid levels were significantly associated with <italic>CRP </italic>(rs1417938) and <italic>TNF </italic>(rs361525), though also not after correction for multiple testing (Table <xref ref-type="table" rid="T4">4</xref>). Serum homocysteine levels were significantly associated with <italic>F2 </italic>(rs1799963)<italic>, MTHFR </italic>(rs1801131, rs1801133, rs2066470) and <italic>ADRB2 </italic>(rs1042713) (Table <xref ref-type="table" rid="T5">5</xref>). However, only rs1801133 remained significant with an FDR-adjusted P value of 0.005. Compared with minimally adjusted models, most associations became more significant in fully adjusted models. The following data for the concentrations of the four biomarkers in relation to the 27 candidate SNPs from minimally-adjusted and fully adjusted models are shown in additional file <xref ref-type="supplementary-material" rid="S1">1</xref> available online (URL): the adjusted least-square means (LSMEANS) and standard errors (SE), exponentiated adjusted LSMEANS (CI), and P values for Satterthwaite adjusted F-statistic.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Sample size and adjusted geometric means (95% confidence intervals) of serum C-reactive protein (mg/dL)*</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Genotype</th><th align="left">Minimally adjusted model LSmean (95% CI)</th><th align="left">P<sub>unadjusted</sub></th><th align="left">P<sub>FDR-adjusted</sub></th><th align="left">Fully adjusted model LSmean (95% CI)</th><th align="left">P<sub>unadjusted</sub></th><th align="left">P<sub>FDR-adjusted</sub></th></tr></thead><tbody><tr><td align="left">rs3093058 (<italic>CRP</italic>)</td><td/><td align="left">0.0013</td><td align="left">0.018</td><td/><td align="left">0.0012</td><td align="left">0.023</td></tr><tr><td align="left">&#x02003;TT</td><td align="left">0.45 (0.29,0.71)</td><td/><td/><td align="left">0.44 (0.29,0.66)</td><td/><td/></tr><tr><td align="left">&#x02003;TA</td><td align="left">0.42 (0.37,0.49)</td><td/><td/><td align="left">0.41 (0.36,0.46)</td><td/><td/></tr><tr><td align="left">&#x02003;AA</td><td align="left">0.32 (0.30,0.34)</td><td/><td/><td align="left">0.32 (0.31,0.33)</td><td/><td/></tr><tr><td align="left">rs1205(<italic>CRP</italic>)</td><td/><td align="left">0.0012</td><td align="left">0.018</td><td/><td align="left">0.0059</td><td align="left">0.038</td></tr><tr><td align="left">AA</td><td align="left">0.28 (0.26,0.31)</td><td/><td/><td align="left">0.29 (0.27, 0.31)</td><td/><td/></tr><tr><td align="left">AG</td><td align="left">0.32 (0.30,0.34)</td><td/><td/><td align="left">0.32 (0.31, 0.34)</td><td/><td/></tr><tr><td align="left">GG</td><td align="left">0.34 (0.32,0.37)</td><td/><td/><td align="left">0.34 (0.32, 0.35)</td><td/><td/></tr><tr><td align="left">rs1801131 (<italic>MTHFR</italic>)</td><td/><td align="left">0.35</td><td align="left">0.71</td><td/><td align="left">0.0024</td><td align="left">0.023</td></tr><tr><td align="left">TT</td><td align="left">0.33 (0.29,0.36)</td><td/><td/><td align="left">0.30 (0.28,0.32)</td><td/><td/></tr><tr><td align="left">TC</td><td align="left">0.32 (0.30,0.34)</td><td/><td/><td align="left">0.32 (0.30,0.33)</td><td/><td/></tr><tr><td align="left">CC</td><td align="left">0.33 (0.31,0.35)</td><td/><td/><td align="left">0.33 (0.32,0.35)</td><td/><td/></tr><tr><td align="left">rs4994 (<italic>ADRB3</italic>)</td><td/><td align="left">0.022</td><td align="left">0.19</td><td/><td align="left">0.0026</td><td align="left">0.023</td></tr><tr><td align="left">CC</td><td align="left">0.29 (0.20,0.42)</td><td/><td/><td align="left">0.29 (0.23, 0.38)</td><td/><td/></tr><tr><td align="left">CT</td><td align="left">0.29 (0.27,0.31)</td><td/><td/><td align="left">0.29 (0.28, 0.31)</td><td/><td/></tr><tr><td align="left">TT</td><td align="left">0.33 (0.31,0.35)</td><td/><td/><td align="left">0.33 (0.31, 0.34)</td><td/><td/></tr></tbody></table><table-wrap-foot><p>Note. *Only associations with unadjusted P (i.e., not adjusted for FDR) &#x02264; 0.05 in fully adjusted models are presented. FDR = false discovery rate.</p></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Adjusted geometric means (95% confidence intervals) of plasma fibrinogen (g/L) *</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Genotype</th><th align="left">Minimally adjusted model LSmean (95% CI)</th><th align="left">P<sub>unadjusted</sub></th><th align="left">P<sub>FDR-adjusted</sub></th><th align="left">Fully adjusted model LSmean (95% CI)</th><th align="left">P<sub>unadjusted</sub></th><th align="left">P<sub>FDR-adjusted</sub></th></tr></thead><tbody><tr><td align="left">rs1800750 (<italic>TNF</italic>)</td><td/><td align="left">0.13</td><td align="left">0.86</td><td/><td align="left">0.013</td><td align="left">0.35</td></tr><tr><td align="left">AA</td><td align="left">3.2 (2.5,4.1)</td><td/><td/><td align="left">2.8 (2.3,3.5)</td><td/><td/></tr><tr><td align="left">AG</td><td align="left">3.4 (2.9,3.9)</td><td/><td/><td align="left">3.5 (3.1,3.9)</td><td/><td/></tr><tr><td align="left">GG</td><td align="left">3.0 (2.9,3.1)</td><td/><td/><td align="left">3.0 (2.9,3.1)</td><td/><td/></tr></tbody></table><table-wrap-foot><p>Note. *Only associations with unadjusted P (i.e., not adjusted for FDR) &#x02264; 0.05 in fully adjusted models are presented. FDR = false discovery rate.</p></table-wrap-foot></table-wrap><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Adjusted geometric means (95% confidence intervals) of serum uric acid (umol/L)*</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Genotype</th><th align="left">Minimally adjusted model LSmean (95% CI)</th><th align="left">P<sub>unadjusted</sub></th><th align="left">P<sub>FDR-adjusted</sub></th><th align="left">Fully adjusted model LSmean (95% CI)</th><th align="left">P<sub>unadjusted</sub></th><th align="left">P<sub>FDR-adjusted</sub></th></tr></thead><tbody><tr><td align="left">rs361525 (<italic>TNF</italic>)</td><td/><td align="center">0.05</td><td align="center">0.76</td><td/><td align="center">0.04</td><td align="center">0.55</td></tr><tr><td align="left">AA</td><td align="left">225 (185-275)</td><td/><td/><td align="center">233 (195-279)</td><td/><td/></tr><tr><td align="left">AG</td><td align="left">258 (248-268)</td><td/><td/><td align="center">257 (246-268)</td><td/><td/></tr><tr><td align="left">GG</td><td align="left">272 (267-278)</td><td/><td/><td align="center">272 (268-276)</td><td/><td/></tr><tr><td align="left">rs1417938 (<italic>CRP</italic>)</td><td/><td align="center">0.16</td><td align="center">0.76</td><td/><td align="center">0.03</td><td align="center">0.55</td></tr><tr><td align="left">TT</td><td align="left">261 (248-273)</td><td/><td/><td align="center">259 (250-270)</td><td/><td/></tr><tr><td align="left">TA</td><td align="left">270 (265-274)</td><td/><td/><td align="center">268 (263-273)</td><td/><td/></tr><tr><td align="left">AA</td><td align="left">273 (267-278)</td><td/><td/><td align="center">274 (268-279)</td><td/><td/></tr></tbody></table><table-wrap-foot><p>Note. *Only associations with unadjusted P (i.e., not adjusted for FDR) &#x02264; 0.05 in fully adjusted models are presented. FDR = false discovery rate.</p></table-wrap-foot></table-wrap><table-wrap id="T5" position="float"><label>Table 5</label><caption><p>Adjusted geometric means (95% confidence intervals) of serum homocysteine (umol/L)*</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Genotype</th><th align="left">Minimally adjusted model LSmean (95% CI)</th><th align="left">P<sub>unadjusted</sub></th><th align="left">P<sub>FDR-adjusted</sub></th><th align="left">Fully adjusted model LSmean (95% CI)</th><th align="left">P<sub>unadjusted</sub></th><th align="left">P<sub>FDR-adjusted</sub></th></tr></thead><tbody><tr><td align="left">rs1801133 (<italic>MTHFR</italic>)</td><td/><td align="left">0.0002</td><td align="left">0.0054</td><td/><td align="left">0.0002</td><td align="left">0.0052</td></tr><tr><td align="left">TT</td><td align="left">9.9 (8.9-11.1)</td><td/><td/><td align="left">9.8 (8.9-10.8)</td><td/><td/></tr><tr><td align="left">TC</td><td align="left">8.2 (8.0-8.5)</td><td/><td/><td align="left">8.2 (7.9-8.5)</td><td/><td/></tr><tr><td align="left">CC</td><td align="left">7.7 (7.5-8.0)</td><td/><td/><td align="left">7.7 (7.6-7.9)</td><td/><td/></tr><tr><td align="left">rs2066470 (<italic>MTHFR</italic>)</td><td/><td align="left">0.05</td><td align="left">0.46</td><td/><td align="left">0.022</td><td align="left">0.28</td></tr><tr><td align="left">TT</td><td align="left">8.2(7.4-9.1)</td><td/><td/><td align="left">8.1 (7.1-9.3)</td><td/><td/></tr><tr><td align="left">TC</td><td align="left">7.8 (7.5-8.1)</td><td/><td/><td align="left">7.7 (7.5-8.0)</td><td/><td/></tr><tr><td align="left">CC</td><td align="left">8.2 (8.0-8.4)</td><td/><td/><td align="left">8.2 (8.0-8.4)</td><td/><td/></tr><tr><td align="left">rs1801131 (<italic>MTHFR</italic>)</td><td/><td align="left">0.02</td><td align="left">0.28</td><td/><td align="left">0.05</td><td align="left">0.28</td></tr><tr><td align="left">CC</td><td align="left">7.9 (7.4-8.4)</td><td/><td/><td align="left">8.0 (7.3-8.8)</td><td/><td/></tr><tr><td align="left">CA</td><td align="left">7.8 (7.6-8.1)</td><td/><td/><td align="left">7.8 (7.5-8.1)</td><td/><td/></tr><tr><td align="left">AA</td><td align="left">8.5 (8.1-8.8)</td><td/><td/><td align="left">8.4 (8.1-8.7)</td><td/><td/></tr><tr><td align="left">rs1799963 (<italic>F2</italic>)</td><td/><td align="left">0.16</td><td align="left">0.85</td><td/><td align="left">0.039</td><td align="left">0.28</td></tr><tr><td align="left">AA</td><td align="left">-<sup>a</sup></td><td align="left">-</td><td/><td align="left">-</td><td/><td/></tr><tr><td align="left">AG</td><td align="left">7.7 (7.1-8.4)</td><td/><td/><td align="left">7.5 (6.9-8.2)</td><td/><td/></tr><tr><td align="left">GG</td><td align="left">8.2 (8.0-8.4)</td><td/><td/><td align="left">8.2 (7.9-8.3)</td><td/><td/></tr><tr><td align="left">rs1042713 (<italic>ADRB2</italic>)</td><td/><td align="left">0.17</td><td align="left">0.85</td><td/><td align="left">0.04</td><td align="left">0.28</td></tr><tr><td align="left">AA</td><td align="left">8.1 (7.7-8.6)</td><td/><td/><td align="left">8.1 (7.7-8.5)</td><td/><td/></tr><tr><td align="left">AG</td><td align="left">8.4 (8.1-8.7)</td><td/><td/><td align="left">8.4 (8.1-8.7)</td><td/><td/></tr><tr><td align="left">GG</td><td align="left">7.9 (7.6-8.2)</td><td/><td/><td align="left">7.8 (7.5-8.2)</td><td/><td/></tr></tbody></table><table-wrap-foot><p>Note. *Only associations with unadjusted P (i.e., not adjusted for FDR) &#x02264; 0.05 in fully adjusted models are presented. FDR = false discovery rate. <sup>a </sup>The frequency is zero for this genotype.</p></table-wrap-foot></table-wrap></sec><sec><title>Discussion</title><p>Cardiovascular diseases are multi-factorial as their pathogenesis is determined by genetic and environmental factors, as well as gene-gene and gene-environment interactions. This population-based genetic association study provides evidence that some intermediate CVD risk markers may be influenced by common genetic variants.</p><p>Numerous candidate gene studies have examined the role of inflammatory gene polymorphisms and the risk of CVD [<xref ref-type="bibr" rid="B41">41</xref>-<xref ref-type="bibr" rid="B45">45</xref>]. However, the findings remain inconsistent and the magnitude of associations remains modest [<xref ref-type="bibr" rid="B46">46</xref>]. C-Reactive protein is a systemic marker of inflammation and plays an important role in the pathogenesis of atherogenesis and its thrombotic complications. Plasma C-Reactive protein concentrations have been associated with <italic>CRP </italic>polymorphisms [<xref ref-type="bibr" rid="B42">42</xref>,<xref ref-type="bibr" rid="B43">43</xref>]. Although C-Reactive protein concentrations are a strong independent predictor of future vascular events, there has been no direct evidence that <italic>CRP </italic>variants contribute to cardiovascular disease phenotypes such as carotid intima-media thickness or arterial thrombosis [<xref ref-type="bibr" rid="B47">47</xref>-<xref ref-type="bibr" rid="B49">49</xref>].</p><p>Fibrinogen plays a key role in the final step of the coagulation cascade, i.e., the formation of fibrin; and it is a major determinant of plasma viscosity and erythrocyte aggregation. There is a large variation on estimates of the genetic heritability of plasma fibrinogen [<xref ref-type="bibr" rid="B44">44</xref>,<xref ref-type="bibr" rid="B45">45</xref>]. The researchers who estimated low heritability argued that environment, rather than genetic influences, has a greater effect on the level of plasma fibrinogen. It is also under debate whether plasma fibrinogen is a primary risk factor/mediator for coronary heart disease, or whether it is a marker for disease [<xref ref-type="bibr" rid="B50">50</xref>]. A large cohort study showed that fibrinogen may partly mediate the effects of other risk factors on carotid atherosclerosis, though it may not play a causal role [<xref ref-type="bibr" rid="B51">51</xref>]. The evidence from molecular biology seems to support the view that fibrinogen is a marker, rather than a mediator, of vascular disease [<xref ref-type="bibr" rid="B52">52</xref>]. Whether the association of plasma fibrinogen with the gene polymorphisms found in this report could be replicated in other genetic association studies remains unknown.</p><p>The findings that serum uric acid levels were associated with <italic>CRP </italic>and <italic>TNF </italic>polymorphisms need to be confirmed by other studies especially because the association was no longer significant after FDR adjustment. The underlying mechanisms need to be examined. In the literature, uric acid levels have been shown to be correlated with plasma levels of circulating TNF-alpha [<xref ref-type="bibr" rid="B53">53</xref>] and increased CRP expression [<xref ref-type="bibr" rid="B24">24</xref>]. Other genetic variants have been found to explain the variance in serum uric acid concentrations [<xref ref-type="bibr" rid="B54">54</xref>-<xref ref-type="bibr" rid="B56">56</xref>].</p><p>Plasma homocysteine is a thiol compound derived from methionine that is involved in two main metabolic pathways: the cycle of activated methyl groups, which requires folate and vitamin B12 as cofactors; and the transsulfuration pathway to cystathionine and cysteine, which requires vitamin B6 as a cofactor. Elevations in plasma homocysteine may be caused by genetic defects in enzymes involved in its metabolism or by deficiencies in cofactor levels [<xref ref-type="bibr" rid="B57">57</xref>]. Although the genetic influence of <italic>MTHFR </italic>polymorphisms on homocysteine levels is well-known, it is under debate whether the <italic>MTHFR </italic>polymorphism per se might be an independent contributor to cardiovascular risk [<xref ref-type="bibr" rid="B58">58</xref>].</p><p>There are some limitations in this study. First, the NHANES DNA bank was set up mainly to assess the allele frequency of these genes in a population-based sample, but it may not necessarily be one of the strong study designs to do genetic association studies. Second, our candidate genes were not selected based solely on explicit molecular/cellular biological pathways. For example, our study shows significant associations between <italic>ADRB3 </italic>and <italic>MTHFR </italic>genes to be associated with concentrations of serum C-reactive proteins although <italic>ADRB3 </italic>was mainly proposed to be a candidate gene for blood pressure and <italic>MTHFR </italic>was for serum homocysteine. The results are not surprising because of complex pathogenetic connections between immuno-inflammatory reactions, elevated homocysteine levels, and high blood pressure [<xref ref-type="bibr" rid="B59">59</xref>,<xref ref-type="bibr" rid="B60">60</xref>]. Third, the four biomarkers investigated in the study are largely influenced by environmental factors which may not be adequately captured by current study.</p><p>We did not investigate whether genetic and environmental factors modify each other in these associations. For example, hormone replacement therapy (especially estrogen) might be associated with increased inflammatory activity [<xref ref-type="bibr" rid="B61">61</xref>]. How genetic factors interact with inflammation-modulating effects of estrogen in causing adverse effects on atherogenesis or determining unfavorable clinical outcome is worthy of further investigation. Further studies are also needed to validate findings from recent genome-wide association studies that have revealed potential new SNPs [<xref ref-type="bibr" rid="B49">49</xref>,<xref ref-type="bibr" rid="B62">62</xref>,<xref ref-type="bibr" rid="B63">63</xref>].</p></sec><sec><title>Conclusion</title><p>Our study provides some evidence that genetic factors contribute to the pathogenesis of inflammation and other CVD risk markers among adult women. Such knowledge may lead to improved prevention and treatment efforts. Identifying the variants that may modify the levels of these risk markers may allow for improved targeting and treatment of individuals or populations at an increased risk for future CVD events.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>AZF conceived of the study, and participated in its design and drafted the manuscript, AY performed the statistical analysis, MH helped drafting the manuscript, MC participated in the design of the study and guided in statistical methodology, JF participated in the design of the study, RN participated study design and interpretation of data, DH participated study design and interpretation of the data. NFD and AHM provided important comments to enrich the discussion. All authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/11/6/prepub">http://www.biomedcentral.com/1471-2350/11/6/prepub</ext-link></p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p><bold>Supplemental Tables</bold>. Table S1. Exponentiated adjusted least-square means of concentrations of the four biomarkers (95% CIs) in relation to the 27 candidate SNPs from minimally-adjusted models. the adjusted least-square means (LSMEANS) and standard errors (SE), exponentiated adjusted LSMEANS (CI), and P values for Satterthwaite adjusted F-statistic are shown. Table S2. Exponentiated adjusted least-square means of concentrations of the four biomarkers (95% CIs) in relation to the 27 candidate SNPs from fully-adjusted models. the adjusted least-square means (LSMEANS) and standard errors (SE), exponentiated adjusted LSMEANS (CI), and P values for Satterthwaite adjusted F-statistic are shown.</p></caption><media xlink:href="1471-2350-11-6-S1.DOC" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><sec><title>Acknowledgements</title><p>The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.</p><p>This project was completed in partnership with the CDC/NCI NHANES III Genomics Working Group.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Rosamond</surname><given-names>W</given-names></name><name><surname>Flegal</surname><given-names>K</given-names></name><name><surname>Friday</surname><given-names>G</given-names></name><name><surname>Furie</surname><given-names>K</given-names></name><name><surname>Go</surname><given-names>A</given-names></name><name><surname>Greenlund</surname><given-names>K</given-names></name><name><surname>Haase</surname><given-names>N</given-names></name><name><surname>Ho</surname><given-names>M</given-names></name><name><surname>Howard</surname><given-names>V</given-names></name><name><surname>Kissela</surname><given-names>B</given-names></name><name><surname>Kittner</surname><given-names>S</given-names></name><name><surname>Lloyd-Jones</surname><given-names>D</given-names></name><name><surname>McDermott</surname><given-names>M</given-names></name><name><surname>Meigs</surname><given-names>J</given-names></name><name><surname>Moy</surname><given-names>C</given-names></name><name><surname>Nichol</surname><given-names>G</given-names></name><name><surname>O'Donnell</surname><given-names>CJ</given-names></name><name><surname>Roger</surname><given-names>V</given-names></name><name><surname>Rumsfeld</surname><given-names>J</given-names></name><name><surname>Sorlie</surname><given-names>P</given-names></name><name><surname>Steinberger</surname><given-names>J</given-names></name><name><surname>Thom</surname><given-names>T</given-names></name><name><surname>Wasserthiel-Smoller</surname><given-names>S</given-names></name><name><surname>Hong</surname><given-names>Y</given-names></name><article-title>Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee</article-title><source>Circulation</source><year>2007</year><volume>115</volume><issue>5</issue><fpage>e69</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.179918</pub-id><pub-id pub-id-type="pmid">17194875</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="book"><collab>National Center for Health Statistics</collab><source>Health, United States, 2008. With Special Features of the Health of Young Adults</source><year>2008</year><publisher-name>Hyattsville, MD: Centers for Disease Control and Prevention</publisher-name><ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/nchs/data/hus/hus08.pdf">http://www.cdc.gov/nchs/data/hus/hus08.pdf</ext-link></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Hackam</surname><given-names>DG</given-names></name><name><surname>Anand</surname><given-names>SS</given-names></name><article-title>Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence</article-title><source>JAMA</source><year>2003</year><volume>290</volume><issue>7</issue><fpage>932</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.1001/jama.290.7.932</pub-id><pub-id pub-id-type="pmid">12928471</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Gillum</surname><given-names>RF</given-names></name><name><surname>Makuc</surname><given-names>DM</given-names></name><article-title>Serum albumin, coronary heart disease, and death</article-title><source>Am Heart J</source><year>1992</year><volume>123</volume><issue>2</issue><fpage>507</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1016/0002-8703(92)90667-K</pub-id><pub-id pub-id-type="pmid">1736588</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Harris</surname><given-names>TB</given-names></name><name><surname>Ferrucci</surname><given-names>L</given-names></name><name><surname>Tracy</surname><given-names>RP</given-names></name><name><surname>Corti</surname><given-names>MC</given-names></name><name><surname>Wacholder</surname><given-names>S</given-names></name><name><surname>Ettinger</surname><given-names>WH</given-names><suffix>Jr</suffix></name><name><surname>Heimovitz</surname><given-names>H</given-names></name><name><surname>Cohen</surname><given-names>HJ</given-names></name><name><surname>Wallace</surname><given-names>R</given-names></name><article-title>Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly</article-title><source>Am J Med</source><year>1999</year><volume>106</volume><issue>5</issue><fpage>506</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1016/S0002-9343(99)00066-2</pub-id><pub-id pub-id-type="pmid">10335721</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Buring</surname><given-names>JE</given-names></name><name><surname>Shih</surname><given-names>J</given-names></name><name><surname>Matias</surname><given-names>M</given-names></name><name><surname>Hennekens</surname><given-names>CH</given-names></name><article-title>Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women</article-title><source>Circulation</source><year>1998</year><volume>98</volume><issue>8</issue><fpage>731</fpage><lpage>733</lpage><pub-id pub-id-type="pmid">9727541</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Cushman</surname><given-names>M</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Tracy</surname><given-names>RP</given-names></name><name><surname>Hennekens</surname><given-names>CH</given-names></name><article-title>Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men</article-title><source>N Engl J Med</source><year>1997</year><volume>336</volume><issue>14</issue><fpage>973</fpage><lpage>979</lpage><pub-id pub-id-type="doi">10.1056/NEJM199704033361401</pub-id><pub-id pub-id-type="pmid">9077376</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Cushman</surname><given-names>M</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Tracy</surname><given-names>RP</given-names></name><name><surname>Hennekens</surname><given-names>CH</given-names></name><article-title>Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease</article-title><source>Circulation</source><year>1998</year><volume>97</volume><issue>5</issue><fpage>425</fpage><lpage>428</lpage><pub-id pub-id-type="pmid">9490235</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Hennekens</surname><given-names>CH</given-names></name><name><surname>Buring</surname><given-names>JE</given-names></name><name><surname>Rifai</surname><given-names>N</given-names></name><article-title>C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women</article-title><source>N Engl J Med</source><year>2000</year><volume>342</volume><issue>12</issue><fpage>836</fpage><lpage>843</lpage><pub-id pub-id-type="doi">10.1056/NEJM200003233421202</pub-id><pub-id pub-id-type="pmid">10733371</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Hennekens</surname><given-names>CH</given-names></name><name><surname>Selhub</surname><given-names>J</given-names></name><name><surname>Miletich</surname><given-names>JP</given-names></name><name><surname>Malinow</surname><given-names>MR</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><article-title>Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism</article-title><source>Circulation</source><year>1997</year><volume>95</volume><issue>7</issue><fpage>1777</fpage><lpage>1782</lpage><pub-id pub-id-type="pmid">9107163</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Koenig</surname><given-names>W</given-names></name><name><surname>Sund</surname><given-names>M</given-names></name><name><surname>Frohlich</surname><given-names>M</given-names></name><name><surname>Fischer</surname><given-names>HG</given-names></name><name><surname>Lowel</surname><given-names>H</given-names></name><name><surname>Doring</surname><given-names>A</given-names></name><name><surname>Hutchinson</surname><given-names>WL</given-names></name><name><surname>Pepys</surname><given-names>MB</given-names></name><article-title>C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992</article-title><source>Circulation</source><year>1999</year><volume>99</volume><issue>2</issue><fpage>237</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">9892589</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Tunstall-Pedoe</surname><given-names>H</given-names></name><name><surname>Woodward</surname><given-names>M</given-names></name><name><surname>Tavendale</surname><given-names>R</given-names></name><name><surname>A'Brook</surname><given-names>R</given-names></name><name><surname>McCluskey</surname><given-names>MK</given-names></name><article-title>Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish Heart Health Study: cohort study</article-title><source>BMJ</source><year>1997</year><volume>315</volume><issue>7110</issue><fpage>722</fpage><lpage>729</lpage><pub-id pub-id-type="pmid">9314758</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Kuller</surname><given-names>LH</given-names></name><name><surname>Tracy</surname><given-names>RP</given-names></name><name><surname>Shaten</surname><given-names>J</given-names></name><name><surname>Meilahn</surname><given-names>EN</given-names></name><article-title>Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial</article-title><source>Am J Epidemiol</source><year>1996</year><volume>144</volume><issue>6</issue><fpage>537</fpage><lpage>547</lpage><pub-id pub-id-type="pmid">8797513</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Rosenson</surname><given-names>RS</given-names></name><name><surname>Koenig</surname><given-names>W</given-names></name><article-title>Utility of inflammatory markers in the management of coronary artery disease</article-title><source>Am J Cardiol</source><year>2003</year><volume>92</volume><issue>1A</issue><fpage>10i</fpage><lpage>18i</lpage><pub-id pub-id-type="doi">10.1016/S0002-9149(03)00504-6</pub-id><pub-id pub-id-type="pmid">12867250</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Danesh</surname><given-names>J</given-names></name><name><surname>Wheeler</surname><given-names>JG</given-names></name><name><surname>Hirschfield</surname><given-names>GM</given-names></name><name><surname>Eda</surname><given-names>S</given-names></name><name><surname>Eiriksdottir</surname><given-names>G</given-names></name><name><surname>Rumley</surname><given-names>A</given-names></name><name><surname>Lowe</surname><given-names>GD</given-names></name><name><surname>Pepys</surname><given-names>MB</given-names></name><name><surname>Gudnason</surname><given-names>V</given-names></name><article-title>C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease</article-title><source>N Engl J Med</source><year>2004</year><volume>350</volume><issue>14</issue><fpage>1387</fpage><lpage>1397</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa032804</pub-id><pub-id pub-id-type="pmid">15070788</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Willerson</surname><given-names>JT</given-names></name><name><surname>Ridker</surname><given-names>PM</given-names></name><article-title>Inflammation as a cardiovascular risk factor</article-title><source>Circulation</source><year>2004</year><volume>109</volume><issue>21 Suppl 1</issue><fpage>II2</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">15173056</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Gagliardi</surname><given-names>AC</given-names></name><name><surname>Miname</surname><given-names>MH</given-names></name><name><surname>Santos</surname><given-names>RD</given-names></name><article-title>Uric acid: A marker of increased cardiovascular risk</article-title><source>Atherosclerosis</source><year>2009</year><volume>202</volume><issue>1</issue><fpage>11</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2008.05.022</pub-id><pub-id pub-id-type="pmid">18585721</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Moat</surname><given-names>SJ</given-names></name><article-title>Plasma total homocysteine: instigator or indicator of cardiovascular disease?</article-title><source>Ann Clin Biochem</source><year>2008</year><volume>45</volume><issue>Pt 4</issue><fpage>345</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1258/acb.2008.008053</pub-id><pub-id pub-id-type="pmid">18583617</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Milani</surname><given-names>RV</given-names></name><name><surname>Lavie</surname><given-names>CJ</given-names></name><article-title>Homocysteine: the Rubik's cube of cardiovascular risk factors</article-title><source>Mayo Clin Proc</source><year>2008</year><volume>83</volume><issue>11</issue><fpage>1200</fpage><lpage>1202</lpage><pub-id pub-id-type="doi">10.4065/83.11.1200</pub-id><pub-id pub-id-type="pmid">18990317</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Hozawa</surname><given-names>A</given-names></name><name><surname>Folsom</surname><given-names>AR</given-names></name><name><surname>Ibrahim</surname><given-names>H</given-names></name><name><surname>Javier Nieto</surname><given-names>F</given-names></name><name><surname>Rosamond</surname><given-names>WD</given-names></name><name><surname>Shahar</surname><given-names>E</given-names></name><article-title>Serum uric acid and risk of ischemic stroke: the ARIC Study</article-title><source>Atherosclerosis</source><year>2006</year><volume>187</volume><issue>2</issue><fpage>401</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2005.09.020</pub-id><pub-id pub-id-type="pmid">16239005</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Leyva</surname><given-names>F</given-names></name><name><surname>Anker</surname><given-names>S</given-names></name><name><surname>Swan</surname><given-names>JW</given-names></name><name><surname>Godsland</surname><given-names>IF</given-names></name><name><surname>Wingrove</surname><given-names>CS</given-names></name><name><surname>Chua</surname><given-names>TP</given-names></name><name><surname>Stevenson</surname><given-names>JC</given-names></name><name><surname>Coats</surname><given-names>AJ</given-names></name><article-title>Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure</article-title><source>Eur Heart J</source><year>1997</year><volume>18</volume><issue>5</issue><fpage>858</fpage><lpage>865</lpage><pub-id pub-id-type="pmid">9152657</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Malinow</surname><given-names>MR</given-names></name><name><surname>Levenson</surname><given-names>J</given-names></name><name><surname>Giral</surname><given-names>P</given-names></name><name><surname>Nieto</surname><given-names>FJ</given-names></name><name><surname>Razavian</surname><given-names>M</given-names></name><name><surname>Segond</surname><given-names>P</given-names></name><name><surname>Simon</surname><given-names>A</given-names></name><article-title>Role of blood pressure, uric acid, and hemorheological parameters on plasma homocyst(e)ine concentration</article-title><source>Atherosclerosis</source><year>1995</year><volume>114</volume><issue>2</issue><fpage>175</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1016/0021-9150(94)05481-W</pub-id><pub-id pub-id-type="pmid">7605386</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Kang</surname><given-names>DH</given-names></name><name><surname>Park</surname><given-names>SK</given-names></name><name><surname>Lee</surname><given-names>IK</given-names></name><name><surname>Johnson</surname><given-names>RJ</given-names></name><article-title>Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells</article-title><source>J Am Soc Nephrol</source><year>2005</year><volume>16</volume><issue>12</issue><fpage>3553</fpage><lpage>3562</lpage><pub-id pub-id-type="doi">10.1681/ASN.2005050572</pub-id><pub-id pub-id-type="pmid">16251237</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Kanellis</surname><given-names>J</given-names></name><name><surname>Kang</surname><given-names>DH</given-names></name><article-title>Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease</article-title><source>Semin Nephrol</source><year>2005</year><volume>25</volume><issue>1</issue><fpage>39</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.semnephrol.2004.09.007</pub-id><pub-id pub-id-type="pmid">15660333</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Cambien</surname><given-names>F</given-names></name><name><surname>Tiret</surname><given-names>L</given-names></name><article-title>Genetics of cardiovascular diseases: from single mutations to the whole genome</article-title><source>Circulation</source><year>2007</year><volume>116</volume><issue>15</issue><fpage>1714</fpage><lpage>1724</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.661751</pub-id><pub-id pub-id-type="pmid">17923582</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Chang</surname><given-names>MH</given-names></name><name><surname>Lindegren</surname><given-names>ML</given-names></name><name><surname>Butler</surname><given-names>MA</given-names></name><name><surname>Chanock</surname><given-names>SJ</given-names></name><name><surname>Dowling</surname><given-names>NF</given-names></name><name><surname>Gallagher</surname><given-names>M</given-names></name><name><surname>Moonesinghe</surname><given-names>R</given-names></name><name><surname>Moore</surname><given-names>CA</given-names></name><name><surname>Ned</surname><given-names>RM</given-names></name><name><surname>Reichler</surname><given-names>MR</given-names></name><name><surname>Sanders</surname><given-names>CL</given-names></name><name><surname>Welch</surname><given-names>R</given-names></name><name><surname>Yesupriya</surname><given-names>A</given-names></name><name><surname>Khoury</surname><given-names>MJ</given-names></name><article-title>Prevalence in the United States of selected candidate gene variants: Third National Health and Nutrition Examination Survey, 1991-1994</article-title><source>Am J Epidemiol</source><year>2009</year><volume>169</volume><issue>1</issue><fpage>54</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1093/aje/kwn286</pub-id><pub-id pub-id-type="pmid">18936436</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Kitsios</surname><given-names>G</given-names></name><name><surname>Zintzaras</surname><given-names>E</given-names></name><article-title>Genetic variation associated with ischemic heart failure: a HuGE review and meta-analysis</article-title><source>Am J Epidemiol</source><year>2007</year><volume>166</volume><issue>6</issue><fpage>619</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.1093/aje/kwm129</pub-id><pub-id pub-id-type="pmid">17644825</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Drenos</surname><given-names>F</given-names></name><name><surname>Whittaker</surname><given-names>JC</given-names></name><name><surname>Humphries</surname><given-names>SE</given-names></name><article-title>The use of meta-analysis risk estimates for candidate genes in combination to predict coronary heart disease risk</article-title><source>Annals of human genetics</source><year>2007</year><volume>71</volume><issue>Pt 5</issue><fpage>611</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1111/j.1469-1809.2007.00359.x</pub-id><pub-id pub-id-type="pmid">17403027</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Zintzaras</surname><given-names>E</given-names></name><name><surname>Zdoukopoulos</surname><given-names>N</given-names></name><article-title>A field synopsis and meta-analysis of genetic association studies in peripheral arterial disease: The CUMAGAS-PAD database</article-title><source>Am J Epidemiol</source><year>2009</year><volume>170</volume><issue>1</issue><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1093/aje/kwp094</pub-id><pub-id pub-id-type="pmid">19435865</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Masuo</surname><given-names>K</given-names></name><name><surname>Katsuya</surname><given-names>T</given-names></name><name><surname>Fu</surname><given-names>Y</given-names></name><name><surname>Rakugi</surname><given-names>H</given-names></name><name><surname>Ogihara</surname><given-names>T</given-names></name><name><surname>Tuck</surname><given-names>ML</given-names></name><article-title>Beta2- and beta3-adrenergic receptor polymorphisms are related to the onset of weight gain and blood pressure elevation over 5 years</article-title><source>Circulation</source><year>2005</year><volume>111</volume><issue>25</issue><fpage>3429</fpage><lpage>3434</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.104.519652</pub-id><pub-id pub-id-type="pmid">15956122</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Balistreri</surname><given-names>CR</given-names></name><name><surname>Colonna-Romano</surname><given-names>G</given-names></name><name><surname>Lio</surname><given-names>D</given-names></name><name><surname>Candore</surname><given-names>G</given-names></name><name><surname>Caruso</surname><given-names>C</given-names></name><article-title>TLR4 polymorphisms and ageing: implications for the pathophysiology of age-related diseases</article-title><source>J Clin Immunol</source><year>2009</year><volume>29</volume><issue>4</issue><fpage>406</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1007/s10875-009-9297-5</pub-id><pub-id pub-id-type="pmid">19459036</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Lawlor</surname><given-names>DA</given-names></name><name><surname>Harbord</surname><given-names>RM</given-names></name><name><surname>Timpson</surname><given-names>NJ</given-names></name><name><surname>Lowe</surname><given-names>GD</given-names></name><name><surname>Rumley</surname><given-names>A</given-names></name><name><surname>Gaunt</surname><given-names>TR</given-names></name><name><surname>Baker</surname><given-names>I</given-names></name><name><surname>Yarnell</surname><given-names>JW</given-names></name><name><surname>Kivimaki</surname><given-names>M</given-names></name><name><surname>Kumari</surname><given-names>M</given-names></name><name><surname>Norman</surname><given-names>PE</given-names></name><name><surname>Jamrozik</surname><given-names>K</given-names></name><name><surname>Hankey</surname><given-names>GJ</given-names></name><name><surname>Almeida</surname><given-names>OP</given-names></name><name><surname>Flicker</surname><given-names>L</given-names></name><name><surname>Warrington</surname><given-names>N</given-names></name><name><surname>Marmot</surname><given-names>MG</given-names></name><name><surname>Ben-Shlomo</surname><given-names>Y</given-names></name><name><surname>Palmer</surname><given-names>LJ</given-names></name><name><surname>Day</surname><given-names>IN</given-names></name><name><surname>Ebrahim</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>GD</given-names></name><article-title>The association of C-reactive protein and CRP genotype with coronary heart disease: findings from five studies with 4,610 cases amongst 18,637 participants</article-title><source>PLoS One</source><year>2008</year><volume>3</volume><issue>8</issue><fpage>e3011</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0003011</pub-id><pub-id pub-id-type="pmid">18714384</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Haider</surname><given-names>DG</given-names></name><name><surname>Leuchten</surname><given-names>N</given-names></name><name><surname>Schaller</surname><given-names>G</given-names></name><name><surname>Gouya</surname><given-names>G</given-names></name><name><surname>Kolodjaschna</surname><given-names>J</given-names></name><name><surname>Schmetterer</surname><given-names>L</given-names></name><name><surname>Kapiotis</surname><given-names>S</given-names></name><name><surname>Wolzt</surname><given-names>M</given-names></name><article-title>C-reactive protein is expressed and secreted by peripheral blood mononuclear cells</article-title><source>Clin Exp Immunol</source><year>2006</year><volume>146</volume><issue>3</issue><fpage>533</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2249.2006.03224.x</pub-id><pub-id pub-id-type="pmid">17100775</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Dedoussis</surname><given-names>GV</given-names></name><name><surname>Panagiotakos</surname><given-names>DB</given-names></name><name><surname>Pitsavos</surname><given-names>C</given-names></name><name><surname>Chrysohoou</surname><given-names>C</given-names></name><name><surname>Skoumas</surname><given-names>J</given-names></name><name><surname>Choumerianou</surname><given-names>D</given-names></name><name><surname>Stefanadis</surname><given-names>C</given-names></name><article-title>An association between the methylenetetrahydrofolate reductase (MTHFR) C677T mutation and inflammation markers related to cardiovascular disease</article-title><source>Int J Cardiol</source><year>2005</year><volume>100</volume><issue>3</issue><fpage>409</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2004.08.038</pub-id><pub-id pub-id-type="pmid">15837084</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Pare</surname><given-names>G</given-names></name><name><surname>Parker</surname><given-names>A</given-names></name><name><surname>Zee</surname><given-names>RY</given-names></name><name><surname>Danik</surname><given-names>JS</given-names></name><name><surname>Buring</surname><given-names>JE</given-names></name><name><surname>Kwiatkowski</surname><given-names>D</given-names></name><name><surname>Cook</surname><given-names>NR</given-names></name><name><surname>Miletich</surname><given-names>JP</given-names></name><name><surname>Chasman</surname><given-names>DI</given-names></name><article-title>Loci related to metabolic-syndrome pathways including LEPR, HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study</article-title><source>Am J Hum Genet</source><year>2008</year><volume>82</volume><issue>5</issue><fpage>1185</fpage><lpage>1192</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2008.03.015</pub-id><pub-id pub-id-type="pmid">18439548</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Reiner</surname><given-names>AP</given-names></name><name><surname>Barber</surname><given-names>MJ</given-names></name><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Lange</surname><given-names>LA</given-names></name><name><surname>Chasman</surname><given-names>DI</given-names></name><name><surname>Walston</surname><given-names>JD</given-names></name><name><surname>Cooper</surname><given-names>GM</given-names></name><name><surname>Jenny</surname><given-names>NS</given-names></name><name><surname>Rieder</surname><given-names>MJ</given-names></name><name><surname>Durda</surname><given-names>JP</given-names></name><name><surname>Smith</surname><given-names>JD</given-names></name><name><surname>Novembre</surname><given-names>J</given-names></name><name><surname>Tracy</surname><given-names>RP</given-names></name><name><surname>Rotter</surname><given-names>JI</given-names></name><name><surname>Stephens</surname><given-names>M</given-names></name><name><surname>Nickerson</surname><given-names>DA</given-names></name><name><surname>Krauss</surname><given-names>RM</given-names></name><article-title>Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein</article-title><source>Am J Hum Genet</source><year>2008</year><volume>82</volume><issue>5</issue><fpage>1193</fpage><lpage>1201</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2008.03.017</pub-id><pub-id pub-id-type="pmid">18439552</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Crawford</surname><given-names>DC</given-names></name><name><surname>Sanders</surname><given-names>CL</given-names></name><name><surname>Qin</surname><given-names>X</given-names></name><name><surname>Smith</surname><given-names>JD</given-names></name><name><surname>Shephard</surname><given-names>C</given-names></name><name><surname>Wong</surname><given-names>M</given-names></name><name><surname>Witrak</surname><given-names>L</given-names></name><name><surname>Rieder</surname><given-names>MJ</given-names></name><name><surname>Nickerson</surname><given-names>DA</given-names></name><article-title>Genetic variation is associated with C-reactive protein levels in the Third National Health and Nutrition Examination Survey</article-title><source>Circulation</source><year>2006</year><volume>114</volume><issue>23</issue><fpage>2458</fpage><lpage>2465</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.615740</pub-id><pub-id pub-id-type="pmid">17101857</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><name><surname>McQuillan</surname><given-names>GM</given-names></name><name><surname>Porter</surname><given-names>KS</given-names></name><name><surname>Agelli</surname><given-names>M</given-names></name><name><surname>Kington</surname><given-names>R</given-names></name><article-title>Consent for genetic research in a general population: the NHANES experience</article-title><source>Genet Med</source><year>2003</year><volume>5</volume><issue>1</issue><fpage>35</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1097/00125817-200301000-00006</pub-id><pub-id pub-id-type="pmid">12544474</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="other"><collab>National Center for Health Statistics</collab><article-title>Laboratory procedures used for NHANES III</article-title><source>Hyattsville, MD</source><year>1994</year><ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/nchs/data/nhanes/nhanes3/cdrom/nchs/manuals/labman.pdf">http://www.cdc.gov/nchs/data/nhanes/nhanes3/cdrom/nchs/manuals/labman.pdf</ext-link></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><name><surname>Gonzalez</surname><given-names>JR</given-names></name><name><surname>Carrasco</surname><given-names>JL</given-names></name><name><surname>Dudbridge</surname><given-names>F</given-names></name><name><surname>Armengol</surname><given-names>L</given-names></name><name><surname>Estivill</surname><given-names>X</given-names></name><name><surname>Moreno</surname><given-names>V</given-names></name><article-title>Maximizing association statistics over genetic models</article-title><source>Genet Epidemiol</source><year>2008</year><volume>32</volume><issue>3</issue><fpage>246</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1002/gepi.20299</pub-id><pub-id pub-id-type="pmid">18228557</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><name><surname>Andreotti</surname><given-names>F</given-names></name><name><surname>Porto</surname><given-names>I</given-names></name><name><surname>Crea</surname><given-names>F</given-names></name><name><surname>Maseri</surname><given-names>A</given-names></name><article-title>Inflammatory gene polymorphisms and ischaemic heart disease: review of population association studies</article-title><source>Heart</source><year>2002</year><volume>87</volume><issue>2</issue><fpage>107</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1136/heart.87.2.107</pub-id><pub-id pub-id-type="pmid">11796541</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><name><surname>Barbaux</surname><given-names>S</given-names></name><name><surname>Tregouet</surname><given-names>DA</given-names></name><name><surname>Nicaud</surname><given-names>V</given-names></name><name><surname>Poirier</surname><given-names>O</given-names></name><name><surname>Perret</surname><given-names>C</given-names></name><name><surname>Godefroy</surname><given-names>T</given-names></name><name><surname>Francomme</surname><given-names>C</given-names></name><name><surname>Combadiere</surname><given-names>C</given-names></name><name><surname>Arveiler</surname><given-names>D</given-names></name><name><surname>Luc</surname><given-names>G</given-names></name><name><surname>Ruidavets</surname><given-names>JB</given-names></name><name><surname>Evans</surname><given-names>AE</given-names></name><name><surname>Kee</surname><given-names>F</given-names></name><name><surname>Morrison</surname><given-names>C</given-names></name><name><surname>Tiret</surname><given-names>L</given-names></name><name><surname>Brand-Herrmann</surname><given-names>SM</given-names></name><name><surname>Cambien</surname><given-names>F</given-names></name><article-title>Polymorphisms in 33 inflammatory genes and risk of myocardial infarction-a system genetics approach</article-title><source>J Mol Med</source><year>2007</year><volume>85</volume><issue>11</issue><fpage>1271</fpage><lpage>1280</lpage><pub-id pub-id-type="doi">10.1007/s00109-007-0234-x</pub-id><pub-id pub-id-type="pmid">17634906</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><name><surname>Visvikis-Siest</surname><given-names>S</given-names></name><name><surname>Marteau</surname><given-names>JB</given-names></name><article-title>Genetic variants predisposing to cardiovascular disease</article-title><source>Curr Opin Lipidol</source><year>2006</year><volume>17</volume><issue>2</issue><fpage>139</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1097/01.mol.0000217895.67444.de</pub-id><pub-id pub-id-type="pmid">16531750</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><name><surname>Hirschhorn</surname><given-names>JN</given-names></name><name><surname>Lohmueller</surname><given-names>K</given-names></name><name><surname>Byrne</surname><given-names>E</given-names></name><name><surname>Hirschhorn</surname><given-names>K</given-names></name><article-title>A comprehensive review of genetic association studies</article-title><source>Genet Med</source><year>2002</year><volume>4</volume><issue>2</issue><fpage>45</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1097/00125817-200203000-00002</pub-id><pub-id pub-id-type="pmid">11882781</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><name><surname>Lohmueller</surname><given-names>KE</given-names></name><name><surname>Pearce</surname><given-names>CL</given-names></name><name><surname>Pike</surname><given-names>M</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Hirschhorn</surname><given-names>JN</given-names></name><article-title>Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease</article-title><source>Nat Genet</source><year>2003</year><volume>33</volume><issue>2</issue><fpage>177</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1038/ng1071</pub-id><pub-id pub-id-type="pmid">12524541</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><name><surname>Arnett</surname><given-names>DK</given-names></name><name><surname>Baird</surname><given-names>AE</given-names></name><name><surname>Barkley</surname><given-names>RA</given-names></name><name><surname>Basson</surname><given-names>CT</given-names></name><name><surname>Boerwinkle</surname><given-names>E</given-names></name><name><surname>Ganesh</surname><given-names>SK</given-names></name><name><surname>Herrington</surname><given-names>DM</given-names></name><name><surname>Hong</surname><given-names>Y</given-names></name><name><surname>Jaquish</surname><given-names>C</given-names></name><name><surname>McDermott</surname><given-names>DA</given-names></name><name><surname>O'Donnell</surname><given-names>CJ</given-names></name><article-title>Relevance of genetics and genomics for prevention and treatment of cardiovascular disease: a scientific statement from the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group</article-title><source>Circulation</source><year>2007</year><volume>115</volume><issue>22</issue><fpage>2878</fpage><lpage>2901</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.107.183679</pub-id><pub-id pub-id-type="pmid">17515457</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Hunt</surname><given-names>SC</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>YE</given-names></name><name><surname>Province</surname><given-names>MA</given-names></name><name><surname>Eckfeldt</surname><given-names>JH</given-names></name><name><surname>Pankow</surname><given-names>JS</given-names></name><name><surname>Song</surname><given-names>Q</given-names></name><article-title>Association study of CRP gene polymorphisms with serum CRP level and cardiovascular risk in the NHLBI Family Heart Study</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2006</year><volume>291</volume><issue>6</issue><fpage>H2752</fpage><lpage>2757</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.01164.2005</pub-id><pub-id pub-id-type="pmid">16731635</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><name><surname>Zee</surname><given-names>RY</given-names></name><name><surname>Ridker</surname><given-names>PM</given-names></name><article-title>Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis</article-title><source>Atherosclerosis</source><year>2002</year><volume>162</volume><issue>1</issue><fpage>217</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1016/S0021-9150(01)00703-1</pub-id><pub-id pub-id-type="pmid">11947917</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><name><surname>Elliott</surname><given-names>P</given-names></name><name><surname>Chambers</surname><given-names>JC</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Clarke</surname><given-names>R</given-names></name><name><surname>Hopewell</surname><given-names>JC</given-names></name><name><surname>Peden</surname><given-names>JF</given-names></name><name><surname>Erdmann</surname><given-names>J</given-names></name><name><surname>Braund</surname><given-names>P</given-names></name><name><surname>Engert</surname><given-names>JC</given-names></name><name><surname>Bennett</surname><given-names>D</given-names></name><name><surname>Coin</surname><given-names>L</given-names></name><name><surname>Ashby</surname><given-names>D</given-names></name><name><surname>Tzoulaki</surname><given-names>I</given-names></name><name><surname>Brown</surname><given-names>IJ</given-names></name><name><surname>Mt-Isa</surname><given-names>S</given-names></name><name><surname>McCarthy</surname><given-names>MI</given-names></name><name><surname>Peltonen</surname><given-names>L</given-names></name><name><surname>Freimer</surname><given-names>NB</given-names></name><name><surname>Farrall</surname><given-names>M</given-names></name><name><surname>Ruokonen</surname><given-names>A</given-names></name><name><surname>Hamsten</surname><given-names>A</given-names></name><name><surname>Lim</surname><given-names>N</given-names></name><name><surname>Froguel</surname><given-names>P</given-names></name><name><surname>Waterworth</surname><given-names>DM</given-names></name><name><surname>Vollenweider</surname><given-names>P</given-names></name><name><surname>Waeber</surname><given-names>G</given-names></name><name><surname>Jarvelin</surname><given-names>MR</given-names></name><name><surname>Mooser</surname><given-names>V</given-names></name><name><surname>Scott</surname><given-names>J</given-names></name><name><surname>Hall</surname><given-names>AS</given-names></name><name><surname>Schunkert</surname><given-names>H</given-names></name><name><surname>Anand</surname><given-names>SS</given-names></name><name><surname>Collins</surname><given-names>R</given-names></name><name><surname>Samani</surname><given-names>NJ</given-names></name><name><surname>Watkins</surname><given-names>H</given-names></name><name><surname>Kooner</surname><given-names>JS</given-names></name><article-title>Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease</article-title><source>JAMA</source><year>2009</year><volume>302</volume><issue>1</issue><fpage>37</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1001/jama.2009.954</pub-id><pub-id pub-id-type="pmid">19567438</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><name><surname>Hamsten</surname><given-names>A</given-names></name><name><surname>Iselius</surname><given-names>L</given-names></name><name><surname>de Faire</surname><given-names>U</given-names></name><name><surname>Blomback</surname><given-names>M</given-names></name><article-title>Genetic and cultural inheritance of plasma fibrinogen concentration</article-title><source>Lancet</source><year>1987</year><volume>2</volume><issue>8566</issue><fpage>988</fpage><lpage>991</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(87)92557-8</pub-id><pub-id pub-id-type="pmid">2889959</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><name><surname>Folsom</surname><given-names>AR</given-names></name><name><surname>Pankow</surname><given-names>JS</given-names></name><name><surname>Williams</surname><given-names>RR</given-names></name><name><surname>Evans</surname><given-names>GW</given-names></name><name><surname>Province</surname><given-names>MA</given-names></name><name><surname>Eckfeldt</surname><given-names>JH</given-names></name><article-title>Fibrinogen, plasminogen activator inhibitor-1, and carotid intima-media wall thickness in the NHLBI Family Heart Study</article-title><source>Thromb Haemost</source><year>1998</year><volume>79</volume><issue>2</issue><fpage>400</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">9493598</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><name><surname>Reinhart</surname><given-names>WH</given-names></name><article-title>Fibrinogen--marker or mediator of vascular disease?</article-title><source>Vasc Med</source><year>2003</year><volume>8</volume><issue>3</issue><fpage>211</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1191/1358863x03vm494ra</pub-id><pub-id pub-id-type="pmid">14989564</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><name><surname>Schulz</surname><given-names>S</given-names></name><name><surname>Schagdarsurengin</surname><given-names>U</given-names></name><name><surname>Suss</surname><given-names>T</given-names></name><name><surname>Muller-Werdan</surname><given-names>U</given-names></name><name><surname>Werdan</surname><given-names>K</given-names></name><name><surname>Glaser</surname><given-names>C</given-names></name><article-title>Relation between the tumor necrosis factor-alpha (TNF-alpha) gene and protein expression, and clinical, biochemical, and genetic markers: age, body mass index and uric acid are independent predictors for an elevated TNF-alpha plasma level in a complex risk model</article-title><source>Eur Cytokine Netw</source><year>2004</year><volume>15</volume><issue>2</issue><fpage>105</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">15319168</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><name><surname>Vitart</surname><given-names>V</given-names></name><name><surname>Rudan</surname><given-names>I</given-names></name><name><surname>Hayward</surname><given-names>C</given-names></name><name><surname>Gray</surname><given-names>NK</given-names></name><name><surname>Floyd</surname><given-names>J</given-names></name><name><surname>Palmer</surname><given-names>CN</given-names></name><name><surname>Knott</surname><given-names>SA</given-names></name><name><surname>Kolcic</surname><given-names>I</given-names></name><name><surname>Polasek</surname><given-names>O</given-names></name><name><surname>Graessler</surname><given-names>J</given-names></name><name><surname>Wilson</surname><given-names>JF</given-names></name><name><surname>Marinaki</surname><given-names>A</given-names></name><name><surname>Riches</surname><given-names>PL</given-names></name><name><surname>Shu</surname><given-names>X</given-names></name><name><surname>Janicijevic</surname><given-names>B</given-names></name><name><surname>Smolej-Narancic</surname><given-names>N</given-names></name><name><surname>Gorgoni</surname><given-names>B</given-names></name><name><surname>Morgan</surname><given-names>J</given-names></name><name><surname>Campbell</surname><given-names>S</given-names></name><name><surname>Biloglav</surname><given-names>Z</given-names></name><name><surname>Barac-Lauc</surname><given-names>L</given-names></name><name><surname>Pericic</surname><given-names>M</given-names></name><name><surname>Klaric</surname><given-names>IM</given-names></name><name><surname>Zgaga</surname><given-names>L</given-names></name><name><surname>Skaric-Juric</surname><given-names>T</given-names></name><name><surname>Wild</surname><given-names>SH</given-names></name><name><surname>Richardson</surname><given-names>WA</given-names></name><name><surname>Hohenstein</surname><given-names>P</given-names></name><name><surname>Kimber</surname><given-names>CH</given-names></name><name><surname>Tenesa</surname><given-names>A</given-names></name><article-title>SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout</article-title><source>Nat Genet</source><year>2008</year><volume>40</volume><issue>4</issue><fpage>437</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1038/ng.106</pub-id><pub-id pub-id-type="pmid">18327257</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><name><surname>Doring</surname><given-names>A</given-names></name><name><surname>Gieger</surname><given-names>C</given-names></name><name><surname>Mehta</surname><given-names>D</given-names></name><name><surname>Gohlke</surname><given-names>H</given-names></name><name><surname>Prokisch</surname><given-names>H</given-names></name><name><surname>Coassin</surname><given-names>S</given-names></name><name><surname>Fischer</surname><given-names>G</given-names></name><name><surname>Henke</surname><given-names>K</given-names></name><name><surname>Klopp</surname><given-names>N</given-names></name><name><surname>Kronenberg</surname><given-names>F</given-names></name><name><surname>Paulweber</surname><given-names>B</given-names></name><name><surname>Pfeufer</surname><given-names>A</given-names></name><name><surname>Rosskopf</surname><given-names>D</given-names></name><name><surname>Volzke</surname><given-names>H</given-names></name><name><surname>Illig</surname><given-names>T</given-names></name><name><surname>Meitinger</surname><given-names>T</given-names></name><name><surname>Wichmann</surname><given-names>HE</given-names></name><name><surname>Meisinger</surname><given-names>C</given-names></name><article-title>SLC2A9 influences uric acid concentrations with pronounced sex-specific effects</article-title><source>Nat Genet</source><year>2008</year><volume>40</volume><issue>4</issue><fpage>430</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1038/ng.107</pub-id><pub-id pub-id-type="pmid">18327256</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Sanna</surname><given-names>S</given-names></name><name><surname>Maschio</surname><given-names>A</given-names></name><name><surname>Busonero</surname><given-names>F</given-names></name><name><surname>Usala</surname><given-names>G</given-names></name><name><surname>Mulas</surname><given-names>A</given-names></name><name><surname>Lai</surname><given-names>S</given-names></name><name><surname>Dei</surname><given-names>M</given-names></name><name><surname>Orru</surname><given-names>M</given-names></name><name><surname>Albai</surname><given-names>G</given-names></name><name><surname>Bandinelli</surname><given-names>S</given-names></name><name><surname>Schlessinger</surname><given-names>D</given-names></name><name><surname>Lakatta</surname><given-names>E</given-names></name><name><surname>Scuteri</surname><given-names>A</given-names></name><name><surname>Najjar</surname><given-names>SS</given-names></name><name><surname>Guralnik</surname><given-names>J</given-names></name><name><surname>Naitza</surname><given-names>S</given-names></name><name><surname>Crisponi</surname><given-names>L</given-names></name><name><surname>Cao</surname><given-names>A</given-names></name><name><surname>Abecasis</surname><given-names>G</given-names></name><name><surname>Ferrucci</surname><given-names>L</given-names></name><name><surname>Uda</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>WM</given-names></name><name><surname>Nagaraja</surname><given-names>R</given-names></name><article-title>The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts</article-title><source>PLoS Genet</source><year>2007</year><volume>3</volume><issue>11</issue><fpage>e194</fpage><pub-id pub-id-type="doi">10.1371/journal.pgen.0030194</pub-id><pub-id pub-id-type="pmid">17997608</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><name><surname>Cortese</surname><given-names>C</given-names></name><name><surname>Motti</surname><given-names>C</given-names></name><article-title>MTHFR gene polymorphism, homocysteine and cardiovascular disease</article-title><source>Public Health Nutr</source><year>2001</year><volume>4</volume><issue>2B</issue><fpage>493</fpage><lpage>497</lpage><pub-id pub-id-type="doi">10.1079/PHN2001159</pub-id><pub-id pub-id-type="pmid">11683544</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><name><surname>Trabetti</surname><given-names>E</given-names></name><article-title>Homocysteine, MTHFR gene polymorphisms, and cardio-cerebrovascular risk</article-title><source>J Appl Genet</source><year>2008</year><volume>49</volume><issue>3</issue><fpage>267</fpage><lpage>282</lpage><pub-id pub-id-type="pmid">18670064</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><name><surname>Bautista</surname><given-names>LE</given-names></name><article-title>Inflammation, endothelial dysfunction, and the risk of high blood pressure: epidemiologic and biological evidence</article-title><source>J Hum Hypertens</source><year>2003</year><volume>17</volume><issue>4</issue><fpage>223</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1038/sj.jhh.1001537</pub-id><pub-id pub-id-type="pmid">12692566</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><name><surname>Lazzerini</surname><given-names>PE</given-names></name><name><surname>Capecchi</surname><given-names>PL</given-names></name><name><surname>Selvi</surname><given-names>E</given-names></name><name><surname>Lorenzini</surname><given-names>S</given-names></name><name><surname>Bisogno</surname><given-names>S</given-names></name><name><surname>Galeazzi</surname><given-names>M</given-names></name><name><surname>Laghi Pasini</surname><given-names>F</given-names></name><article-title>Hyperhomocysteinemia, inflammation and autoimmunity</article-title><source>Autoimmun Rev</source><year>2007</year><volume>6</volume><issue>7</issue><fpage>503</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1016/j.autrev.2007.03.008</pub-id><pub-id pub-id-type="pmid">17643940</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><name><surname>Stork</surname><given-names>S</given-names></name><name><surname>Schouw</surname><given-names>YT van der</given-names></name><name><surname>Grobbee</surname><given-names>DE</given-names></name><name><surname>Bots</surname><given-names>ML</given-names></name><article-title>Estrogen, inflammation and cardiovascular risk in women: a critical appraisal</article-title><source>Trends Endocrinol Metab</source><year>2004</year><volume>15</volume><issue>2</issue><fpage>66</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2004.01.005</pub-id><pub-id pub-id-type="pmid">15036252</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><name><surname>Malarstig</surname><given-names>A</given-names></name><name><surname>Buil</surname><given-names>A</given-names></name><name><surname>Souto</surname><given-names>JC</given-names></name><name><surname>Clarke</surname><given-names>R</given-names></name><name><surname>Blanco-Vaca</surname><given-names>F</given-names></name><name><surname>Fontcuberta</surname><given-names>J</given-names></name><name><surname>Peden</surname><given-names>J</given-names></name><name><surname>Andersen</surname><given-names>M</given-names></name><name><surname>Silveira</surname><given-names>A</given-names></name><name><surname>Barlera</surname><given-names>S</given-names></name><name><surname>Seedorf</surname><given-names>U</given-names></name><name><surname>Watkins</surname><given-names>H</given-names></name><name><surname>Almasy</surname><given-names>L</given-names></name><name><surname>Hamsten</surname><given-names>A</given-names></name><name><surname>Soria</surname><given-names>JM</given-names></name><article-title>Identification of ZNF366 and PTPRD as novel determinants of plasma homocysteine in a family-based genome-wide association study</article-title><source>Blood</source><year>2009</year><volume>114</volume><issue>7</issue><fpage>1417</fpage><lpage>1422</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-04-215269</pub-id><pub-id pub-id-type="pmid">19525478</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><name><surname>Bis</surname><given-names>JC</given-names></name><name><surname>Glazer</surname><given-names>NL</given-names></name><name><surname>Psaty</surname><given-names>BM</given-names></name><article-title>Genome-wide association studies of cardiovascular risk factors: design, conduct and interpretation</article-title><source>J Thromb Haemost</source><year>2009</year><volume>7</volume><issue>Suppl 1</issue><fpage>308</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1111/j.1538-7836.2009.03392.x</pub-id><pub-id pub-id-type="pmid">19630823</pub-id></mixed-citation></ref></ref-list></back></article>